Prostate-specific antigen doubling time as a prognostic marker in prostate cancer

被引：0
|
作者：
James A Eastham
机构：
[1] surgeon in the Department of Urology at Memorial Sloan–Kettering Cancer Center,
来源：
Nature Clinical Practice Urology | 2005年 / 2卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
There is much debate surrounding the suitability and utility of different prognostic markers in prostate cancer. PSA doubling time (PSADT) has become an important marker in predicting the response to salvage radiotherapy and progression to metastatic disease in men with biochemical failure following local therapy. The methods of calculating PSADT and its use as a prognostic marker are discussed in this review by James Eastham.
引用
收藏
页码：482 / 491
页数：9
相关论文
共 50 条
  • [31] PROSTATE-SPECIFIC ANTIGEN AS A SERUM MARKER FOR ADENOCARCINOMA OF THE PROSTATE
    STAMEY, TA
    YANG, N
    HAY, AR
    MCNEAL, JE
    FREIHA, FS
    REDWINE, E
    NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (15): : 909 - 916
  • [32] EVALUATION OF PROSTATE-SPECIFIC ANTIGEN AS A MARKER FOR ADENOCARCINOMA OF THE PROSTATE
    BARAK, M
    MECZ, Y
    LURIE, A
    GRUENER, N
    JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 1989, 113 (05): : 598 - 603
  • [33] Prostate specific antigen (PSA) as a diagnostic and prognostic marker of prostate cancer
    Simon, Ronald
    Kluth, Martina
    Fischer, Kristine
    Bonk, Sarah
    Hube-Magg, Claudia
    Hoflmayer, Doris
    Lennartz, Maximilian
    Lutz, Florian
    Sauter, Guido
    Buescheck, Franziska
    Uhlig, Ria
    Dum, David
    Luebke, Andreas M.
    Wittmer, Corinna
    Jacobsen, Frank
    Burandt, Eike
    Steurer, Stefan
    Minner, Waldemar Wilczakand Sarah
    CANCER RESEARCH, 2019, 79 (13)
  • [34] Editorial Comment to Association of prostate-specific antigen doubling time and cancer in men undergoing repeat prostate biopsy
    Shimbo, Masaki
    INTERNATIONAL JOURNAL OF UROLOGY, 2012, 19 (08) : 747 - 748
  • [35] Prostate-specific antigen doubling time and response to cabazitaxel in a hormone-resistant metastatic prostate cancer patient
    Marwan Ghosn
    Alain Dagher
    Fadi El-Karak
    TheJournalofBiomedicalResearch, 2015, 29 (05) : 420 - 422
  • [36] Prostate-specific antigen doubling time and response to cabazitaxel in a hormone-resistant metastatic prostate cancer patient
    Ghosn, Marwan
    Dagher, Alain
    El-Karak, Fadi
    JOURNAL OF BIOMEDICAL RESEARCH, 2015, 29 (05): : 420 - 422
  • [37] Prostate-specific antigen doubling time as a progression criterion in an active surveillance programme for patients with localized prostate cancer
    Thomsen, Frederik Birkebaek
    Christensen, Ib Jarle
    Brasso, Klaus
    Roder, Martin Andreas
    Iversen, Peter
    BJU INTERNATIONAL, 2014, 113 (5B) : E98 - E105
  • [38] Prostate-specific antigen doubling time: A potential surrogate end point in hormone-refractory prostate cancer
    Schmid, HP
    Semjonow, A
    Maibach, R
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (05) : 1645 - 1646
  • [39] Implications of prostate-specific antigen doubling time as indicator of failure after surgery or radiation therapy for prostate cancer
    Maffezzini, Massimo
    Bossi, Alberto
    Collette, Lautence
    EUROPEAN UROLOGY, 2007, 51 (03) : 605 - 613
  • [40] Limitation of prostate-specific antigen doubling time as a predictor of outcome in hormone-naive prostate cancer.
    Nelson, J. B.
    Sleep, D. J.
    Isaacson, J. D.
    Carducci, M. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 233S - 233S
12345